Results 301 to 310 of about 1,299,020 (330)

Podoplanin-positive cell-derived small extracellular vesicles contribute to cardiac amyloidosis after myocardial infarction. [PDF]

Cell Rep
Cimini M, Hansmann UHE, Gonzalez C, Chesney AD, Truongcao MM, Gao E, Wang T, Roy R, Forte E, Mallaredy V, Thej C, Magadum A, Joladarashi D, Benedict C, Koch WJ, Tükel Ç, Kishore R.   +16 more
europepmc   +1 more source

Midventricular Obstruction With Diastolic Paradoxic Jet Flow in Transthyretin Cardiac Amyloidosis: A Case Report. [PDF]

Cureus
Nishiki E, Honda S, Yamano M, Kawasaki T.   +3 more
europepmc   +1 more source

Left bundle branch area pacing in patients with transthyretin cardiac amyloidosis: a case series. [PDF]

Eur Heart J Case Rep
Miyajima K, Kobayashi W, Hakamata S, Takazawa Y, Kawaguchi Y, Wakabayashi Y, Maekawa Y.   +6 more
europepmc   +1 more source

Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis. [PDF]

Egypt Heart J
Huang W, Frederich A, Nurhafizah A, Salma AD, Zahrani RAF, Retnoningrum IA.   +5 more
europepmc   +1 more source

Transthyretin Cardiac Amyloidosis in a Very Elderly Patient With a History of Inferior Myocardial Infarction: A Case Report. [PDF]

Cureus
Kurisu S, Fujiwara H.
europepmc   +1 more source

Acute Mitral Papillary Muscle Rupture Secondary to Cardiac Amyloidosis. [PDF]

Ann Thorac Surg Short Rep
Nagase T, Kashiyama N, Horikawa N, Sakai N, Ryugo M, Monta O, Tsutsumi Y, Oda S.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiac amyloidosis

Current Treatment Options in Cardiovascular Medicine, 1999
No definitive therapy is available for cardiac amyloidosis. Treatment with alkylating agents such as melphalan has improved survival. Patients who do not respond to melphalan have benefited from high-dose chemotherapy with cyclophosphamide followed by peripheral stem cell transplantation.
Jeffrey D. Hosenpud, Kiran Kashyap
openaire   +3 more sources

CT Extracellular Volume Fraction versus Myocardium-to-Lumen Signal Ratio for Cardiac Amyloidosis.

Radiology, 2022
Background Large studies on the diagnostic performance of CT-derived myocardial extracellular volume fraction (ECV) for detecting cardiac amyloidosis are lacking. A simple and practical index as a surrogate for CT ECV would be clinically useful.
M. Kidoh, S. Oda, S. Takashio, Kyoko Hirakawa, Y. Kawano, S. Shiraishi, Hidetaka Hayashi, T. Nakaura, Y. Nagayama, Y. Funama, Mitsuharu Ueda, K. Tsujita, T. Hirai   +12 more
semanticscholar   +1 more source

Cardiac Amyloidosis Due to Transthyretin Protein: A Review.

Journal of the American Medical Association (JAMA)
Importance Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomyopathy. Observations Transthyretin (TTR) protein transports thyroxine (thyroid hormone) and retinol (vitamin A) and is ...
F. Ruberg, Mathew S. Maurer
semanticscholar   +1 more source

Cardiac amyloidosis

Clinical and Translational Imaging, 2019
Purpose: The aim of the present article was to review the recent developments in diagnosis, prognostication and management of cardiac amyloidosis. Methods: Available scientific literature on cardiac amyloidosis has been critically reviewed. Results: Different precursors cause different forms of cardiac amyloidosis with different outcomes and ...
Giorgetti, Assuero, Genovesi, Dario, Milan, Elisa, Acampa, Wanda, Giubbini, Raffaele, Cuocolo, Alberto, Marzullo, Paolo   +6 more
openaire   +2 more sources